{"DataElement":{"publicId":"5990054","version":"1","preferredName":"Prostate Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for prostate carcinoma, using AJCC Ed. 8 criteria.","longName":"PROS_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5997103","version":"1","preferredName":"Prostate Gland Neoplasm Stage Grouping","preferredDefinition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"2206573v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206573","version":"1","preferredName":"Prostate Neoplasm","preferredDefinition":"A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS):(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12410:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Gland","conceptCode":"C12410","definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FA7A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"5B203816-0588-3342-E053-F662850A5C25","latestVersionIndicator":"Yes","beginDate":"2017-10-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-09","modifiedBy":"TAYLORT","dateModified":"2018-12-05","changeDescription":"12/5/18 tmt released. 10/9/17 Created for standard harmonization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6032159","version":"1","preferredName":"Prostate Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of prostate cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.).__An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6032159v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"I","valueDescription":"Stage I Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032183","version":"1","preferredName":"Stage I Prostate Cancer AJCC v8","longName":"6032183","preferredDefinition":"Stage I includes: (cT1a-c, cT2a, N0, M0, PSA less than 10, Grade Group 1); (pT2, N0, M0, PSA less than 10, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. pT2: Prostate cancer which is organ confined. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Prostate Cancer AJCC v8","conceptCode":"C140164","definition":"Stage I includes: (cT1a-c, cT2a, N0, M0, PSA less than 10, Grade Group 1); (pT2, N0, M0, PSA less than 10, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. pT2: Prostate cancer which is organ confined. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-7084-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9C67-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Stage IIA Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032179","version":"1","preferredName":"Stage IIA Prostate Cancer AJCC v8","longName":"6032179","preferredDefinition":"Stage IIA includes: (cT1a-c, cT2a, N0, M0, PSA equal or more than 10 and less than 20, Grade Group 1); (cT2b-c, N0, M0, PSA less than 20, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. cT2b: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. cT2c: Prostate cancer in which the tumor involves both sides. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Prostate Cancer AJCC v8","conceptCode":"C140166","definition":"Stage IIA includes: (cT1a-c, cT2a, N0, M0, PSA equal or more than 10 and less than 20, Grade Group 1); (cT2b-c, N0, M0, PSA less than 20, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. cT2b: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. cT2c: Prostate cancer in which the tumor involves both sides. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-7038-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9C7B-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Stage IIB Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032177","version":"1","preferredName":"Stage IIB Prostate Cancer AJCC v8","longName":"6032177","preferredDefinition":"Stage IIB includes: T1-2, N0, M0, PSA less than 20, Grade Group 2. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Prostate Cancer AJCC v8","conceptCode":"C140167","definition":"Stage IIB includes: T1-2, N0, M0, PSA less than 20, Grade Group 2. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-7012-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9C8F-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IIC","valueDescription":"Stage IIC Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032175","version":"1","preferredName":"Stage IIC Prostate Cancer AJCC v8","longName":"6032175","preferredDefinition":"Stage IIC includes: (T1-2, N0, M0, PSA less than 20, Grade Group 3); (T1-2, N0, M0, PSA less than 20, Grade Group 4). T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIC Prostate Cancer AJCC v8","conceptCode":"C140168","definition":"Stage IIC includes: (T1-2, N0, M0, PSA less than 20, Grade Group 3); (T1-2, N0, M0, PSA less than 20, Grade Group 4). T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-6FEC-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9CA3-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032171","version":"1","preferredName":"Stage IIIA Prostate Cancer AJCC v8","longName":"6032171","preferredDefinition":"Stage IIIA includes: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Prostate Cancer AJCC v8","conceptCode":"C140170","definition":"Stage IIIA includes: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-6FA0-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9CB7-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032169","version":"1","preferredName":"Stage IIIB Prostate Cancer AJCC v8","longName":"6032169","preferredDefinition":"Stage IIIB includes: T3-4, N0, M0, PSA: Any, Grade Group 1-4; T3: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. T4: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Prostate Cancer AJCC v8","conceptCode":"C140171","definition":"Stage IIIB includes: T3-4, N0, M0, PSA: Any, Grade Group 1-4; T3: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. T4: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-6F7A-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9CCB-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032167","version":"1","preferredName":"Stage IIIC Prostate Cancer AJCC v8","longName":"6032167","preferredDefinition":"Stage IIIC includes: Any T, N0, M0, PSA: Any, Grade Group 5. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 5: Gleason Score 9 or 10, Gleason Pattern 4+5, or 5+4, or 5+5. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Prostate Cancer AJCC v8","conceptCode":"C140172","definition":"Stage IIIC includes: Any T, N0, M0, PSA: Any, Grade Group 5. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 5: Gleason Score 9 or 10, Gleason Pattern 4+5, or 5+4, or 5+5. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-6F54-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9CDF-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032163","version":"1","preferredName":"Stage IVA Prostate Cancer AJCC v8","longName":"6032163","preferredDefinition":"Stage IVA includes: Any T, N1, M0, PSA: Any, Grade Group: Any. N1: Prostate cancer with metastases in regional node(s). M0: Prostate cancer without evidence of distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Prostate Cancer AJCC v8","conceptCode":"C140174","definition":"Stage IVA includes: Any T, N1, M0, PSA: Any, Grade Group: Any. N1: Prostate cancer with metastases in regional node(s). M0: Prostate cancer without evidence of distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-6F08-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9CF3-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Prostate Cancer AJCC v8","ValueMeaning":{"publicId":"6032161","version":"1","preferredName":"Stage IVB Prostate Cancer AJCC v8","longName":"6032161","preferredDefinition":"Stage IVB includes: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Prostate Cancer AJCC v8","conceptCode":"C140175","definition":"Stage IVB includes: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E92D8B2-6EE2-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64063835-9D07-1144-E053-F662850A8CEF","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6059351","version":"1","preferredName":"Prostate Cancer by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of prostate cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C140163:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer by AJCC v8 Stage","conceptCode":"C140163","definition":"A term that refers to the staging of prostate cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"64063835-9B33-1144-E053-F662850A8CEF","latestVersionIndicator":"Yes","beginDate":"2018-01-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5E92D8B2-6EBC-4F9F-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"TAYLORT","dateModified":"2018-12-05","changeDescription":"12/5/18 tmt released. 11/22/17 tt created for standardization, associated with CS/CSI; supercedes 3436543.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000015","version":"1","longName":"Prostate","context":"NCI Standards"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"5635376","version":"1","longName":"Prostate","context":"OCCPR"},{"publicId":"6779561","version":"1","longName":"PRAD Baseline","context":"OCCPR"}]}],"AlternateNames":[{"name":"MCL","type":"USED_BY","context":"MCL"},{"name":"OCCPR","type":"USED_BY","context":"OCCPR"},{"name":"ajcc_8_prostate_disease_stage","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"},{"name":"CPTAC-BSLN-1","type":"Alternate Question Text","description":"Tumor Stage (Pathologic)","url":null,"context":"OCCPR"},{"name":"MCL-PCA-prostate-1","type":"Alternate Question Text","description":"American Joint Committee on Cancer clinical group stage","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5AE6067A-A460-1267-E053-F662850AF8B1","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-06","modifiedBy":"COLBERTM","dateModified":"2021-09-30","changeDescription":"9/30/21 mr Added alt name, AQT, alt def, ref doc, CSI per MCL prostate DD.   12/5/18 tmt released. 11/22/17 tt associated with VD and CS/CSI. 10/9/17 tt Associated with new DEC. 10/6/17 tt Created for standard harmonization. Incomplete pending updates to VD per NCIt Ed 8 caDSR concept loading; supercedes CDE 3436566.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}